Amgen is developing a biosimilar of the drug, ABP 959, and during last week’s 24th Congress of the European Hematology Association, held from June 13-16 in Amsterdam, the Netherlands, researchers reported on findings from a phase 1 trial of the proposed product.
Eculizumab (Alexion’s Soliris) is used to treat generalized myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and atypical hemolytic uremic syndrome, all rare and ultra-rare diseases. While effective in treating these diseases, the complement inhibitor is among the highest-cost biologics on the market, carrying a list price of approximately $500,000 per patient per year.
Amgen is developing a biosimilar of the drug, ABP 959, and during last week’s 24th Congress of the European Hematology Association, held June 13-16 in Amsterdam, the Netherlands, researchers reported on findings from a phase 1 trial of the proposed product.
The randomized, double-blind, single-dose, 3-arm, parallel-group study was conducted in 219 healthy volunteers. The volunteers were randomized to receive a 300-mg intravenous infusion of either the proposed biosimilar (n = 71), the EU reference (n = 74), or the US reference (n = 74). Serum samples were collected over 56 days.
The primary objectives were to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of the proposed biosimilar versus the EU and US references, assessed by area under the total serum concentration—time curve (AUC) from time 0 extrapolated to infinity (AUCinf) and area between the effect curve (ABEC) of 50% total hemolytic complement activity (CH50).
Secondary PK endpoints included AUC from time 0 to the time of the last observed quantifiable concentration (AUClast) and maximum observed concentration (Cmax)
The geometric mean ratios of the PK and PD parameters after a single infusion were similar among all 3 groups; the 90% confidence intervals of the geometric mean ratios were fully contained within the prespecified bioequivalence margin of 0.80 to 1.25 for all PK (AUCinf, Cmax, AUClast) and PD (ABEC of CH50) evaluations.
There were no treatment-emergent adverse events (AEs) that led to discontinuation, nor were there any deaths. Five volunteers experienced a total of 8 serious AEs. In total, 8.8% of volunteers had binding antidrug antibodies during the study, and no neutralizing antibodies were detected.
According to the authors, these data show the PK and PD equivalence of the proposed biosimilar to eculizumab, and demonstrated similar safety and immunogenicity profiles.
Reference
Chow V, Pan J, Chien D, Mytych D, Hanes V. Pharmacokinetic and pharmacodynamic similarity of ABP 959 with eculizumab: results from a randomized, double-blind, single-dose, parallel-group study in healthy subjects. Presented at: the 24th European Hematology Association Congress; June 13-16, 2019; Amsterdam, the Netherlands. Abstract PF347.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.